Ixico secures new contract valued at more than $750,000

Ixico said on Wednesday that it had inked a new imaging master vendor agreement with an unnamed "top-five global clinical research organisation" to support its sponsor's Phase II Alzheimer's disease clinical trial.

The AIM-listed group said being selected as a dedicated imaging vendor was also expected to "significantly enhance" its opportunity to partner with the CRO's client portfolio.

Chief executive Giulio Cerroni said: "One of the core elements of our commercial growth strategy has been to establish strong relationships with select therapeutically aligned partner CROs. This enables greater access to new biopharmaceutical clients and accelerates the adoption of our proprietary neuroimaging technology solutions, at scale.

"Our mission is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders. This new award reflects the confidence that CROs and sponsors place in Ixico, as their trusted neuroimaging partner for their pivotal CNS studies."

As of 1115 BST, Ixico shares were up 6.68% at 78.94p.